

# Mitophagy upregulation as a therapeutic strategy for Alzheimers disease

<https://www.neurodegenerationresearch.eu/survey/mitophagy-upregulation-as-a-therapeutic-strategy-for-alzheimers-disease/>

## Principal Investigators

BOHR, VILHELM A

## Institution

National Institute on Aging

## Contact information of lead PI

### Country

USA

## Title of project or programme

Mitophagy upregulation as a therapeutic strategy for Alzheimers disease

## Source of funding information

NIH (NIA)

## Total sum awarded (Euro)

122853.211

## Start date of award

## Total duration of award in years

1

## Keywords

Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Brain Disorders... Dementia... Health Disparities for IC Use... Neurodegenerative... Neurosciences

## Research Abstract

We seek to explore the relationship between mitochondrial dysfunction and accumulation of damaged mitochondria in AD. We have established *C. elegans* models to investigate whether mitophagy contributes to AD pathology. We have detected mitochondrial quality in wild type (N2) and hu-Tau or Abeta-overexpressed AD *C. elegans* models (RB809/ptl-1 (ok621); BR5270 (byls161); CL2120 (dvls14); CL2355) using confocal microscopy, electron microscopy, and Seahorse respirometry. All the AD worms showed accumulation of damaged mitochondria,

impaired mitochondrial network, and decreased basal oxygen consumption. We propose that defective mitophagy contributes to accumulation of damaged mitochondria in AD. Mitophagy will be evaluated using multiple techniques such as immunoblotting for protein expression, a mitophagy reporter worm strain, mitophagy dyes, and the mt-mKeima reporter. Our preliminary data indicate defective mitophagy in Tau and Abeta overexpressing cells. In the future, we apply therapeutic strategies to modulate mitophagy and offset AD mitochondrial phenotypes. We will investigate whether mitophagy induction can improve healthspan endpoints (swimming movement; pharyngeal pumping; maximum velocity), and extend lifespan of AD worms models.

**Further information available at:**

**Types:**

Investments < €500k

**Member States:**

United States of America

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A